Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Inclusion Criteria: * Male and female subjects aged 18-65 years, inclusive * BMI \>18 and \<40 * Minimum affected BSA of 10% * PASI score ≥ 12 * PGA ≥ 3 * Diagnosed with moderate-to-severe plaque psoriasis Exclusion Criteria: * Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis * History of an allergic reaction or known and/or significant sensitivity to study drug